In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs ...

TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing ...

While MIC2025 was officially shelved from public discourse in 2018 due to intense international backlash, its core objectives ...

At a fully automated production line in south China's Guangxi Zhuang Autonomous Region, cans of energy drinks rolled off ...

Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...

On May 9, 2025, the Tianjin Municipal Administration for Market Regulation (“Tianjin AMR”) announced administrative penalties ...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

The China NMPA's CDE has granted breakthrough therapy designation approval to Abbisko Therapeutics’ irpagratinib for HCC.